Status:
COMPLETED
Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
Lead Sponsor:
Pfizer
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
By leveraging a community-based, cancer-specific electronic healthcare record for this study, we aim to understand treatment patterns and clinical outcomes among patients with HR+/HER2- mBC who receiv...
Eligibility Criteria
Inclusion
- Documented diagnosis of HR+/HER2- mBC
- Initiated palbociclib + fulvestrant as first-line therapy in the metastatic setting and had at least 2 visits following the index date
- Received care at a US oncology site(s) utilizing the full EHR at time of treatment and data are available for research purposes
Exclusion
- Enrollment in an interventional clinical trial during the study period
- Evidence of prior treatment with CDK4/6 inhibitors in the metastatic setting
- Receipt of treatment indicated for another primary cancer during the study period or history of another primary cancer documented within the US Oncology EHR.
Key Trial Info
Start Date :
October 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
317 Patients enrolled
Trial Details
Trial ID
NCT04460911
Start Date
October 19 2019
End Date
April 1 2022
Last Update
January 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer United States
New York, New York, United States, 10017